German researchers who performed 123I-MIBG SPECT on 42 patients with definite arrhythmogenic right ventricular cardiomyopathy found that those with abnormal results experienced life-threatening ventricular tachyarrhythmias more often. The patients were monitored for 11.9 years. The "observed predisposition to future ventricular tachyarrhythmias in patients with a reduced 123I-MIBG uptake could eventually lead to the recognition of 123I-MIBG SPECT as an indicator of an increased individual risk of future arrhythmic events," according to the study published in the Journal of Nuclear Medicine.

Related Summaries